This article is more than 5 years old. Information may no longer be current.
Periprocedural MI similar between first-, second-generation DES
Study results published in Catheterization and Cardiovascular Interventions have found no significant difference in the incidence of periprocedural MI between first- and second-generation drug-eluting stents.
Researchers assessed the rate of periprocedural MI in 800 patients treated with first-generation DES Taxus Liberté (Boston Scientific) or Endeavor (Medtronic) or second-generation DES Resolute (Medtronic Vascular) or Xience V (Abbott Vascular) using the current Academic Research Consortium (ARC) definition. Patients had stable angina, unstable angina or non-STEMI and received DES between February 2007 and January 2009. Each DES group was composed of 200 consecutive patients treated during the transition from first- to second-generation DES.
Investigators performed routine peri-interventional assessment of cardiac biomarkers to compare the incidence of periprocedural MI between DES groups according to the updated definition by the ARC, which is twice the upper reference limit of creatine kinase (CK) confirmed by CK-MB elevation.
Overall, there was no significant difference in periprocedural MI between generations of DES (first-generation, 5.5% vs. second-generation, 4%; P=.29). In multivariate analysis, independent predictors of periprocedural MI included the total number of stents implanted (P<.001) and presentation with ACS (P=.02).
“The main finding of this study is that in a broad spectrum of clinical settings the incidence of periprocedural MI was similar for first and second-generation DES, despite more multivessel PCI in patients who received second-generation DES,” the researchers wrote.